NDA 022311 · Genzyme
Mozobil
Plerixafor · Subcutaneous · Hematopoietic Stem Cell Mobilizer
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Sep 21, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2008
Dec 15, 2008
Approved uses
1
Original approval plus efficacy supplements
Registered trials
166
8 Phase 3, 14 recruiting
FAERS reports
1,485
1,174 serious, 244 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 19, 2025.
Plerixafor is indicated in combination with filgrastim to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM). Plerixafor, a hematopoietic stem cell mobilizer, is indicated in combination with filgrastim to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma or multiple myeloma. ( 1 )
Mechanism: Plerixafor is an inhibitor of the CXCR4 chemokine receptor and blocks binding of its cognate ligand, stromal cell-derived factor-1α (SDF-1α). SDF-1α and CXCR4 are recognized to play a role in the trafficking and homing of human hematopoietic stem cells (HSCs) to the marrow compartment. Once in the marrow, stem cell CXCR4 can act to help anchor these cells to the marrow matrix, either directly via SDF-1α or through the induction of other adhesion molecules. Treatment with plerixafor resulted in leukocytosis and elevations in circulating hematopoietic progenitor cells in mice, dogs and humans....
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 15, 2008 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanReviewLetterLabel
1 products under this application
- MOZOBIL · PLERIXAFOR 24MG/1.2ML (20MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Plerixafor" as an intervention, any sponsor and status, largest first.
- Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma PatientsPivotal-lookingCompleted
Genzyme, a Sanofi CompanySanofi (SNY)
NCT00103662 · 302 participants · Start Jan 2005 · Primary completion Oct 2006
Drug: Granulocyte colony-stimulating factor plus plerixafor; Granulocyte colony-stimulating factor plus placebo · For: Multiple Myeloma
Sites: Phoenix, Arizona; Little Rock, Arkansas; Duarte, California · 39 sites in all
- Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma PatientsPivotal-lookingCompleted
Genzyme, a Sanofi CompanySanofi (SNY)
NCT00103610 · 298 participants · Start Jan 2005 · Primary completion Jul 2006
Drug: Granulocyte colony-stimulating factor plus plerixafor; Granulocyte colony-stimulating factor plus placebo · For: Lymphoma, Non-Hodgkin
Sites: Phoenix, Arizona; Duarte, California; Denver, Colorado · 32 sites in all
National Cancer Institute (NCI)NIH
NCT05470491 · 265 participants (planned) · Start Jan 26, 2023 · Primary completion Jul 30, 2027
Drug: RIC; GVHD prophylaxis and 2 more · For: HIV; Hematologic Malignancies
Sites: Bethesda, Maryland
- Plerixafor for Poorly Mobilized LymphomaStatus unknown
Peking UniversityAcademic, hospital or other
NCT05510544 · 140 participants (planned) · Start Dec 19, 2022 · Primary completion Dec 20, 2023
Drug: Plerixafor,G-CSF · For: Lymphoma
Sites: Beijing, China
Center for International Blood and Marrow Transplant ResearchResearch network
NCT01696461 · 127 participants · Start May 2013 · Primary completion Aug 2016
Drug: Plerixafor · For: Related Donors Donating Peripheral Blood Stem Cells (PBSC) to a Family Member; Acute Myelogenous Leukemia; Acute Lymphoblastic Leukemia and 5 more
Sites: Tampa, Florida; Atlanta, Georgia; Chicago, Illinois · 12 sites in all
Genzyme, a Sanofi CompanySanofi (SNY)
NCT00838357 · 118 participants · Start Sep 2008 · Primary completion Nov 2010
Drug: Generic = Plerixafor · For: Lymphoma (Non-Hodgkin's Lymphoma); Hodgkin's Disease or Multiple Myeloma; Front Line Mobilization and 1 more
Sites: Bordeaux, France; Lyon, France; Marseille, France · 26 sites in all
Cardiff UniversityAcademic, hospital or other
NCT01236144 · 113 participants · Start Apr 2011 · Primary completion Dec 2013
Drug: Plerixafor; AC220 and 1 more · For: Acute Myeloid Leukaemia; High Risk Myelodysplastic Syndrome
Sites: Aberdeen, United Kingdom; Belfast, United Kingdom; Birmingham, United Kingdom · 13 sites in all
- Study Assessing Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MGTA-145 in Healthy Volunteers as a Single Agent or in Combination With PlerixaforPivotal-lookingCompleted
EnsomaIndustry
NCT03932864 · 107 participants · Start Apr 22, 2019 · Primary completion Feb 25, 2020
Drug: MGTA-145; plerixafor and 1 more · For: Healthy Volunteers
Sites: Cincinnati, Ohio
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- febrile neutropenia144
- off label use127
- diarrhoea100
- pyrexia86
- mucosal inflammation83
- nausea82
- thrombocytopenia82
- death60
- plasma cell myeloma60
- pneumonia58
- neutropenia57
- vomiting57
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2009 | 20 |
| 2010 | 41 |
| 2011 | 73 |
| 2012 | 114 |
| 2013 | 74 |
| 2014 | 49 |
| 2015 | 53 |
| 2016 | 48 |
| 2017 | 69 |
| 2018 | 62 |
| 2019 | 107 |
| 2020 | 139 |
| 2021 | 204 |
| 2022 | 86 |
| 2023 | 75 |
| 2024 | 127 |
| 2025 | 94 |
| 2026 | 50 |
Recalls
2 FDA enforcement reports for this application.
Sep 1, 2016 · Class III · Terminated
Labeling: Incorrect or Missing Package Insert
Aug 4, 2016 · Class III · Terminated
Labeling: Incorrect or Missing Lot and/or Exp. Date
Shortages
FDA's drug shortage list.
To Be Discontinued · updated Mar 13, 2026
Plerixafor, Injection, 24 mg per 1.2 mL (20 mg per mL) (NDC 65219-284-12). A business decision was made to discontinue manufacture of the drug.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Mozobil* (Plerixafor*) · HCPCS J2562
2024 spending
$6.1M
Beneficiaries
1,360
2,068 claims
Per beneficiary
$4,449
2024 ASP limit $118.59 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $17,787,709 |
| 2021 | $18,573,469 |
| 2022 | $22,411,107 |
| 2023 | $23,487,370 |
| 2024 | $6,051,040 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- WBC Growth Factors: ASCO Guideline Update.
Gyawali B, Bohlke K, Dickter JK, et al. · J Clin Oncol 2026 · Practice Guideline, Systematic Review
- Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.
Voorhees PM, Kaufman JL, Laubach J, et al. · Blood 2020 · Clinical Trial, Phase II, Multicenter Study
- Gateways to clinical trials.
Bayes M, Rabasseda X, Prous JR · Methods Find Exp Clin Pharmacol 2006 · Clinical Trial
- Stem cell mobilization with plerixafor and healing of diabetic ischemic wounds: A phase IIa, randomized, double-blind, placebo-controlled trial.
Bonora BM, Cappellari R, Mazzucato M, et al. · Stem Cells Transl Med 2020 · Clinical Trial, Phase II, Randomized Controlled Trial
- A new step in understanding stem cell mobilization in patients with Fanconi anemia: A bridge to gene therapy.
Diana JS, Manceau S, Leblanc T, et al. · Transfusion 2022 · Clinical Trial, Phase I, Clinical Trial, Phase II
- The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome.
McDermott DH, Liu Q, Ulrick J, et al. · Blood 2011 · Clinical Trial, Phase I, Research Support, N.I.H., Extramural
Sponsor: Sanofi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.